Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks on Jim Cramer’s radar recently. When a caller asked about the stock during the lightning round, Cramer stated: “I don’t know. It’s ...

In the latest close session, Recursion Pharmaceuticals (RXRX) was down 5.42% at $5.23. The stock fell short of the S&P 500, which registered a loss of 0.38% for the day. Meanwhile, the Dow experienced ...

Recursion Pharmaceuticals (RXRX) shares ended the last trading session 8.2% higher at $5.52. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Best Penny Stocks to Buy with the Highest Upside Potential. On September 10, Gil Blum from Needham reiterated a Buy rating on Recursion ...

This data feed is not available at this time. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.

Recursion Pharmaceuticals (NASDAQ:RXRX), a $2.06 billion market cap biotech company, saw Chief Executive Officer Christopher Gibson sell 100,000 shares of Class A Common Stock on September 25, 2025, ...

Community driven content discussing all aspects of software development from DevOps to design patterns. If a developer finds out that there are new, updated files on a remote repository like GitHub, ...

TIOBE Index for October 2025: Top 10 Most Popular Programming Languages Your email has been sent The October TIOBE Programming Community Index brought a few quiet but meaningful shifts. Python remains ...